CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
通用型 CAR-T 细胞治疗——细胞治疗的未来：一项提供临床证据的综述
英文原题：Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.
查看英文原题
Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
自体CAR-T 疗法在过去几年中在肿瘤治疗中显示出良好的前景，尤其是血液系统恶性肿瘤。然而，由于患者和/或外周血特征不理想、制造成本高且周期长以及其他挑战，自体CAR-T 疗法的应用受到限制。通用型CAR-T 疗法可以克服自体CAR-T 疗法的主要局限性。在这篇综述中，我们描述了通用型CAR-T 疗法用于血液系统恶性肿瘤的研发现状。此外，我们还总结了所遇到的挑战及当前的解决方案。
展开英文摘要原文
Autologous CAR-T therapy has shown promising outcomes in the treatment of tumors, particularly hematological malignancies over the past years.
However, the application of autologous CAR-T therapy is limited, due to undesirable patient and/or peripheral blood characteristics, the high cost and long time period of manufacturing, and other challenges. Universal CAR-T therapy could overcome major limitations of autologous CAR-T therapy. In this review, we described the research and development status of universal CAR-T therapy for hematological malignancies.
In addition, we also summarized the challenges had been encountered and the current solutions.
论文信息
- 作者
- Sun W、Jiang Z、Jiang W、Yang R
- 第一作者单位
- Gobroad Healthcare Group, Beijing, China.China
- 通讯作者单位
- Gobroad Healthcare Group, Beijing, China. Electronic address: rui.yang@gobroadaro.com.China
- 文献类型
- 综述
- 期刊
- Cancer treatment and research communications2022
- 原文标识
- PubMed 36184307 · DOI 10.1016/j.ctarc.2022.100638